Ruchaneekorn W. KalpravidhNoppadol SiritanaratkulPraphaipit InsainRatiya CharoensakdiNarumol PanichkulSuneerat HatairakthamSomdet SrichairatanakoolChada PhisalaphongEliezer RachmilewitzSuthat FucharoenMahidol UniversityChiang Mai UniversityThailand Government Pharmaceutical OrganizationEdith Wolfson Medical Center IsraelThe Institute of Science and Technology for Research and Development, Mahidol University2018-09-242018-09-242010-03-01Clinical Biochemistry. Vol.43, No.4-5 (2010), 424-429000991202-s2.0-76749103354https://repository.li.mahidol.ac.th/handle/20.500.14594/28779Objectives: To evaluate the hematological profile, oxidative stress, and antioxidant parameters in β-thalassemia/Hb E patients treated with curcuminoids for 12 months. Design and methods: Twenty-one β-thalassemia/Hb E patients were given 2 capsules of 250 mg each of curcuminoids (a total of 500 mg) daily for 12 months. Blood was collected every 2 months during treatment and 3 months after withdrawal and was determined for complete blood count, malonyldialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), reduced glutathione (GSH) in red blood cells (RBC), and non-transferrin bound iron (NTBI) in serum. Results: The increased oxidative stress in β-thalassemia/Hb E patients was shown by higher levels of MDA, SOD, GSH-Px in RBC, serum NTBI, and lower level of RBC GSH. Curcuminoids administration resulted in improvement of all the measured parameters as long as they were administered. After 3 months withdrawal of treatment, all parameters returned close to baseline levels. Conclusion: Curcuminoids may be used to ameliorate oxidative damage in patients with β-thalassemia/Hb E disease. © 2009 The Canadian Society of Clinical Chemists.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1016/j.clinbiochem.2009.10.057